23andMe Brings CE Marked Personal Genome Service® to the UK

23andMe Brings CE Marked Personal Genome Service® to the UK

Learn from over 100 reports on health and personal traits; discover genetic lineage and potentially find new relatives

Mountain View, Calif. 2nd December 2014: 23andMe, the leading personal genetics company, today announced the launch of its CE marked Personal Genome Service® in the UK, with more than 100 reports offering health, trait and ancestry information. UK citizens will now have simple, affordable access to their personal genetic information to explore more about themselves, including health, ancestry and the genetics behind interesting traits they may share with their family.

"23andMe's mission is to ensure that individuals can personally access, understand and benefit from the human genome," said 23andMe CEO Anne Wojcicki. "The UK is a world leader in genomics and we are very excited to offer a product specifically for UK customers."

The 23andMe Personal Genome Service (PGS) is not a diagnostic but includes results for genes associated with certain inherited conditions such as Cystic Fibrosis or Sickle Cell Anaemia. The PGS also tests for genes that may reveal risk factors for certain diseases or conditions such as blood clotting, Alzheimer's disease or Parkinson's disease, and how your body may respond to specific medications, such as Warfarin or Hepatitis C treatments.

On top of what you can learn about your health, you can also explore the genetics behind why you may be a more frequent smoker, how you metabolize caffeine and how your body may respond to diet and exercise. You can also learn more about traits such as your ability to detect certain odors and whether or not you are predisposed to be a sprinter or endurance athlete.

The PGS also provides a full genetic ancestry report, so you can trace your family's genetic roots, and potentially discover and communicate with new relatives as part of 23andMe's DNA Relatives feature.

Following Research Ethics Committee review and approval, UK customers will also have the opportunity to participate in the world's largest online platform for genetic research. To date more than 600,000 23andMe customers have elected to participate in research, helping the 23andMe research team identify hundreds of new genetic associations.

The UK is considered a world leader in genetic research and has seen huge scientific innovation and government investment in this area over recent years. The recent launch of Genomics England's 100,000 Genome project1 (to sequence 100,000 genomes of patients with cancer or rare diseases) made the UK a priority country in which to launch 23andMe to help give all people affordable access to their own genetic information.

Evidence from existing 23andMe customers based in the UK revealed that over 70 percent of customers found their reports "extremely valuable". A quarter had shared the results with their doctor but only 4 percent had requested additional testing or made a special appointment with their doctor to discuss the results.2

23andMe's Personal Genome Service was developed with a focus on individual genetic markers that are widely accepted and have been published in respected scientific literature. Information for UK customers was specifically informed by key stakeholders and professional associations in the UK and abroad.

23andMe's Personal Genome Service is available for purchase at www.23andMe.co.uk for £125 including shipping. All new 23andMe customers in the UK will have access to health and trait reports beginning December 2, 2014. Any existing customers in the UK who purchased 23andMe on November 22, 2013 through December 1, 2014 will also have immediate access to 23andMe health and trait reports for free.


Genomics England 100,000 Genomes Project: http://www.genomicsengland.co.uk/ Last accessed November 2014.
Data on file: 23andMe conducted an online survey with a random sample of its UK customers who received health and trait reports. A total of 470 customers answered the survey, representative of the 23andMe UK customer base in terms of age and gender. Results are accurate at the 95 percent confidence interval with an error margin of +/- 4 percent.
About 23andMe

23andMe, Inc. is the leading personal genetics company dedicated to helping people access, understand and benefit from the human genome. he company's Personal Genome Service® enables individuals in the UK to gain deeper insights into their health and ancestry. The vision for 23andMe is to personalize healthcare by making and supporting meaningful discoveries through genetic research. 23andMe, Inc., was founded in 2006, and the company is advised by a group of renowned experts in the fields of human genetics, bioinformatics and computer science. More information is available at www.23andme.co.uk. 23andMe's health reports are not cleared by the FDA; UK health reports can only be purchased in the UK, by UK residents. US customers may purchase 23andMe's ancestry-only product, which provides access to their un-interpreted raw genetic data as well.
Media Contact(s)

For more information please contact:

Beth Williams, Weber Shandwick

+44 20 7067 0664

[email protected]

Laetitia Laporte, Weber Shandwick

+44 20 7067 0552

[email protected]

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.